NCT03556956

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Masitinib in Combination With FOLFIRI Versus Masitinib Alone, Versus Best Supportive Care, in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 219 (actual)
• Sponsor: AB Science · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective, multicentre, open-label, randomized, phase 2-3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer

Detailed description

The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care in third or fourth line treatment of patients with metastatic colorectal cancer.

Conditions

• Colorectal Cancer Metastatic

Interventions

Type	Name	Description
DRUG	Masitinib	Tyrosine kinase inhibitor

Timeline

• Start date: 2015-07-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2018-06-14
• Last updated: 2020-12-08

Locations

5 sites across 5 countries: Czechia, France, Russia, Spain, United Kingdom

Regulatory

• FDA-regulated drug study